medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 4

<< Back Next >>

Med Int Mex 2021; 37 (4)

Infections associated to the health care

Casanova-Cardiel LJ, Estrada-Tapia LL, Amezcua-Rentería A

Language: Spanish
References: 28
Page: 484-493
PDF size: 438.50 Kb.


ABSTRACT

Objective: To report the epidemiology and bacterial sensitivities to various antibiotics in infections associated to the health care at the General Hospital of Ciudad Juarez, Chihuahua, Mexico.
Materials and Methods: A study was done reviewing the records of infections associated to the health care from January 2013 to December 2015 at the Infectology Service of General Hospital of Ciudad Juarez, Chihuahua, Mexico.
Results: There were 370 infections. Phlebitis 105 (28%), 26 isolates (25%): 20 staphylococci, 13 (65%) methicillin-resistant. Surgical wound infection 64 (17%), 45 isolates (70%): 19 (42%) Gram-positive, 16 staphylococci, 63% methicillin-resistant and 26 (58%) Gram-negative, with 69% resistance to cephalosporins, 50% to quinolones, 11% to carbapenem. Ventilator-associated pneumonia 60 (16%) 32 positive cultures (53%): 13 staphylococci, 8 (62%) methicillin-resistant, 8 S. aureus, 4 (50%) methicillin-resistant, and 19 Gram-negatives, 9 P. aeruginosa, 4 (44%) multi-drug resistant. Urinary tract infection 58 (15.6%), 43 isolates (74%), 36 Gram-negative: 10 (28%) resistant to amikacin, 22 (61%) to ceftriaxone, 20 (55%) to cefepime, 23 (64%) to ciprofloxacin, 11 (31%) to carbapenems, 4 (11%) to piperacillin/tazobactam, 7 (19%) to ticarcillin/clavulanate.
Conclusions: Empirical antibiotic scheme to start in our hospital is carbapenem plus amikacin, with vancomycin; since E. coli and/or P. aeruginosa and S. aureus are potential. Cephalosporin and quinolones should not be administered.


REFERENCES

  1. Revelas A. Healthcare–associated infections: A public health problem. Niger Med J 2012; 53: 59-64. http://dx.doi. org/10.4103%2F0300-1652.103543.

  2. Samuel SO, Kayode OO, Musa OI, Nwigwe GC, et al. Nosocomial infections and the challenges of control in developing countries. Afr J Cln Exper Microbiol 2010; 11: 102-10. doi. 10.4314/ajcem.v11i2.53916.

  3. Laxminarayan R, Duse A, Wattal C, Zaidi A, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis 2013; 13: 1057-98. http://dx.doi.org/10.1016/S1473- 3099(13)70318-9.

  4. Obama B. Executive Order -- Combating Antibiotic-Resistant Bacteria. The White House Office of the Press Secretary 2014. Recuperado de https://www.whitehouse.gov/ the-press-office/2014/09/18/executive-order-combatingantibiotic- resistant-bacteria.

  5. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Rev Antimicrob Resist May 2016.

  6. Allegranzi B, Nejad SB, Combescure C, Graafmans W, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and metaanalysis. Lancet 2010; 377: 228-41. doi. 10.1016/S0140- 6736(10)61458-4.

  7. Secretaría de Salud. Norma Oficial Mexicana 045 NOM- 045-SSA2-2005, Para la vigilancia epidemiológica, prevención y control de las infecciones nosocomiales. Diario Oficial de la Federación 20/11/2009. Recuperado de http://dof.gob.mx/nota_detalle.php?codigo=5120943 &fecha=20/11/2009.

  8. Fridkin S. What Healthcare-Associated Infections are resistant in your state? Medscape Multispeciality. News & Perspective 2016. Recuperado de: http://www.medscape. com/viewarticle/865511?nlid=108075_801&src=W NL_mdplsfeat_160712_mscpedit_infd&uac=32644BV&s pon=3&impID=1154358&faf=1.

  9. Casanova-Cardiel LJ. Consideraciones sobre infecciones nosocomiales. Med Int Mex 2004; 20: 140-3.

  10. Centers for Diseases Control and Prevention. Making Health Care Safer. Protect patients from antibiotic resis tance. Vital Signs 2016. Recuperado de: http://www.cdc. gov/vitalsigns/protect-patients/index.html

  11. Friedman C, Newsom W. Conceptos básicos de control de infecciones. International Federation of Infection Control, 2011 (2nd ed.). http://theific.org/wp-content/ uploads/2014/08/Spanish_front_PRESS.pdf.

  12. Peterson LR, Hamilton JD, Baron EJ, Tompkins LS, et al. Role of clinical microbiology laboratory in the management and control of infectious diseases and the delivery of health care. Clin Infect Dis 2001; 32: 605-11. doi. 10.1086/318725.

  13. Johnston BL, Conly JM. Clostridium difficile: The evolving story. Can J Infect Dis Med Microbiol 2007; 18: 341-5. doi. 10.1155/2007/615827.

  14. Kwok CS, Arthur AK, Anibueze CI, Singh S, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-9. doi. 10.1038/ajg.2012.108.

  15. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372: 1539-48. doi. 10.1056/NEJMra1403772.

  16. Lessa FC, Mu Y, Bamberg WM, Beldavs Z, et al. Burden of Clostridium difficile Infection in United States. N Engl J Med 2015; 372: 825-34. doi. 10.1056/NEJMoa1408913.

  17. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.

  18. Enright MC, Robinson DA, Randle G, Feil EJ, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci 2002; 99: 7687-92. doi. 10.1073/pnas.122108599.

  19. Saïd-Salim B, Mathema B, Kreiswirth BN. Communityacquired methicillin-resistant Staphylococcus aureus: An emerging pathogen. Infect Control Hosp Epidemiol 2003; 24: 451-5. doi. 10.1086/502231.

  20. Barros EM, Ceotto H, Bastos MCF, dos Santos KRN, et al. Staphylococcus haemolyticus as an important hospital pathogen and carrier of methicillin resistance genes. J Clin Microbiol 2012; 50: 166-8. doi. 10.1128J/CM.05563-11.

  21. O’Driscoll T, Crank CW. Vancomycin-resistance enterococcal infections: epidemiology, clinical manifestations and optimal management. Infect Drug Resist 2015; 8: 217-30. doi. http://dx.doi.org/10.2147%2FIDR.S54125.

  22. Casanova-Cardiel LJ, Castañón-González J. Reflexiones acerca del lavado de manos. Rev Med IMSS 2004; 42: 519-24.

  23. McGann P, Snesrud E, Maybank R, Corey B, et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: First report of mcr-1 in the USA. Antimicrob Agents Chemother 2016; 60: 4420-1 doi. 10.1128/AAC.01103-16.

  24. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa Part I: Epidemiology, clinical diagnosis, and source. Chest 2011; 139: 909-19. https:// doi.org/10.1378/chest.10-0166.

  25. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa Part II: Antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 2011; 139: 1172-85. https://doi.org/10.1378/ chest.10-0167.

  26. Petty NK, Ben-Zakour NL, Stanton-Cook M, Skippington E, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci 2014; 111: 5694-9 doi. 10.1073/pnas.1322678111.

  27. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-36 doi. 10.1111/j.1469- 0691.2006.01456.x.

  28. Zimlichman E, Henderson D, Tamir O, Franz C, et al. Health care–associated infections a meta-analysis of costs and financial impact on the US Health Care System. JAMA Intern Med 2013; 173: 2039-46. doi. 10.1001/jamainternmed. 2013.9763.




2020     |     www.medigraphic.com